Trial Profile

A Randomised, Double-blind, Placebo and Positive Controlled, Phase 2 Clinical Trial to Evaluate the Safety and Immunogenicity of 15-valent Human Papillomavirus Recombinant Vaccine (Hansenulapolymorpha) in Healthy Chinese People Aged 9-45 Years

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 21 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Human papillomavirus recombinant vaccine 15 valent Shanghai Bovax Biotechnology (Primary) ; Human papillomavirus recombinant vaccine nonavalent - Shanghai Bovax Biotechnology
Indications Human papillomavirus infections
Focus Adverse reactions
Sponsors Shanghai Bovax Biotechnology

17 Dec 2025 Actual primary completion date is 30 Oct 2025.
17 Dec 2025 Status changed to recruiting.
07 Feb 2025 Status changed from not yet recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com